AAPG Key Statistics, Chart & Performance
The current stock price of AAPG is 32.37 USD. In the past month the price decreased by -6.34%.
AAPG Latest News, Press Relases and Analysis
AAPG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.49B | ||
| AMGN | AMGEN INC | 15.6 | 183.64B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.76 | 110.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.75 | 56.34B | ||
| INSM | INSMED INC | N/A | 44.18B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.87 | 26.68B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 21.97B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About AAPG
Company Profile
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The firm mainly conducts its business in the domestic market.
Company Info
ASCENTAGE PHARMA GR-ADR
68 Xinqing Road, Suzhou Industrial Park
Suzhou JIANGSU CN
Employees: 605
ASCENTAGE PHARMA GR-ADR / AAPG FAQ
What does AAPG do?
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The firm mainly conducts its business in the domestic market.
Can you provide the latest stock price for ASCENTAGE PHARMA GR-ADR?
The current stock price of AAPG is 32.37 USD. The price increased by 1.06% in the last trading session.
What is the dividend status of ASCENTAGE PHARMA GR-ADR?
AAPG does not pay a dividend.
What is the ChartMill technical and fundamental rating of AAPG stock?
AAPG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in ASCENTAGE PHARMA GR-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AAPG.
What is ASCENTAGE PHARMA GR-ADR worth?
ASCENTAGE PHARMA GR-ADR (AAPG) has a market capitalization of 3.01B USD. This makes AAPG a Mid Cap stock.
AAPG Technical Analysis
AAPG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AAPG. AAPG may be in some trouble as it scores bad on both profitability and health.
AAPG Financial Highlights
Over the last trailing twelve months AAPG reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS decreased by -184.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.05% | ||
| ROE | -174.06% | ||
| Debt/Equity | 1.99 |
AAPG Forecast & Estimates
13 analysts have analysed AAPG and the average price target is 39.73 USD. This implies a price increase of 22.73% is expected in the next year compared to the current price of 32.37.
For the next year, analysts expect an EPS growth of -186.08% and a revenue growth -42.1% for AAPG